HC Wainwright Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Analysts at HC Wainwright cut their Q1 2026 earnings estimates for Nkarta in a research report issued to clients and investors on Thursday, March 26th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.40) per share for the quarter, down from their previous estimate of ($0.34). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($1.66) EPS, FY2029 earnings at ($1.49) EPS and FY2030 earnings at ($1.13) EPS.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a report on Monday, December 29th. Needham & Company LLC lifted their target price on shares of Nkarta from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wall Street Zen lowered Nkarta from a “hold” rating to a “sell” rating in a report on Saturday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $12.00.

Nkarta Price Performance

Shares of NASDAQ:NKTX opened at $2.06 on Monday. The business’s 50 day moving average is $2.28 and its 200 day moving average is $2.10. Nkarta has a 12-month low of $1.42 and a 12-month high of $2.81. The stock has a market cap of $153.04 million, a price-to-earnings ratio of -1.47 and a beta of 0.47.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05).

Insiders Place Their Bets

In other news, CEO Paul J. Hastings sold 26,046 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $2.07, for a total transaction of $53,915.22. Following the completion of the transaction, the chief executive officer directly owned 390,023 shares of the company’s stock, valued at $807,347.61. This represents a 6.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nkarta

Hedge funds have recently modified their holdings of the stock. GSK plc purchased a new position in Nkarta during the fourth quarter valued at approximately $5,829,000. Jane Street Group LLC increased its holdings in Nkarta by 118.7% during the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock worth $247,000 after acquiring an additional 852,559 shares during the period. Millennium Management LLC purchased a new stake in Nkarta in the 3rd quarter worth approximately $1,549,000. Monaco Asset Management SAM boosted its holdings in Nkarta by 29.2% in the 4th quarter. Monaco Asset Management SAM now owns 2,546,932 shares of the company’s stock valued at $4,712,000 after purchasing an additional 576,022 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Nkarta by 48.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,702,022 shares of the company’s stock valued at $3,149,000 after purchasing an additional 556,945 shares during the period. Institutional investors own 80.54% of the company’s stock.

More Nkarta News

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: HC Wainwright’s price target (reported by American Banking News) was increased to $11.00 — a constructive signal about long‑term upside potential and program value that could support buying interest. Read More.
• Negative Sentiment: HC Wainwright sharply cut EPS forecasts across multiple quarters and years in its March 26 research note: Q1 2026 to ($0.40) from ($0.34), Q2 to ($0.42) from ($0.36), Q3 to ($0.45) from ($0.38), Q4 to ($0.47) from ($0.41), FY2026 to ($1.74) from ($1.50), and material downgrades for FY2027–FY2030 (e.g., FY2027 now ($2.12) from ($1.84)). These lower model inputs signal slower cash runway/longer development timelines or higher costs, which is negative for the stock’s near‑term valuation. Read More.
• Negative Sentiment: Wall Street Zen lowered its rating on Nkarta to “Sell” (reported by American Banking News), a direct negative for sentiment and potential catalyst for additional selling from fund managers or momentum traders. Read More.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.